Tag Archive for: DynamiCure

ImaginAb Executes License and Supply Agreement for CD8 ImmunoPET Technology with DynamiCure Biotechnology

Los Angeles, California, USA, November 15, 2022 – ImaginAb Inc., a global biotechnology company focused on developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPETTM) imaging agent and radiopharmaceutical therapy (RPT) products, today announced the signing of a new multi-year, non-exclusive license agreement with DynamiCure Biotechnology, a private biopharmaceutical company developing innovative therapeutic antibody candidates to treat cancer, […]